Effects of Heparin on the Vessel Wall and Blood Cellular Elements

McLean J. The thromboplastic effect of cephalin. Am J Physiol 1916; 41: 250–57.

Howell W H Holt E. Two new factors in blood coagulation — heparin and pro-antithrombin. Am J Physiol 1922; 47: 328–41.

Lindahl U. Bäckström G. Thunberg L. The antithrombin-binding sequence in heparin. J Biol Chem 1983; 258: 9826–30.

Hiebert L M Jaques L. B. The observation of heparin on enodthelium after injection. Thromb Res 1976; 8: 195–204.

Gensini G F Fortini A. Lombardi A. . Binding of low molecular weight heparin to aortic endothelium in rabbits. Haemostasis 1984; 14: 466–72.

Van Rijn J L M L Trillou M. Mardiguian J. Tobelem G. Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211–22.

Bikfalvi A. Dupuy E. Ruan C. Tobelem G. Leseche G. Caen J. Binding of heparin to human microvascular endothelial cells and the effect on proliferation. Cell Biol Int Rep 1988; 12: 931–42.

Bârzu T. Van Rijn J L M L Petitou M. Molho P. Tobelem G. Caen J. P. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986; 238: 847–54.

Herbert J-M Maffrand J-P. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: Incidence on vascular smooth muscle cell proliferation. J Cell Physiol 1989; 138: 424–32.

Dawes J. Pepper D. S. Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost 1992; 67: 468–72.

Thornton S C Mueller S N Levine E. M. Human endothelial cells: Use of heparin in cloning and long-term serial cultivation. Science 1983; 222: 623–25.

Folkman J. Ingber D. E. Angiogenesis: Regulatory role of heparin and related molecules. In: Lane D A Lindahl U. eds. Heparin. Chemical and biological properties; clinical applications. London: Edward Arnold, 1989; 317–34.

D'Amore P. A. Heparin–endothelial cell interactions. Haemostasis 1990; 20: 159–65.

Cariou R. Harousseau J L Tobelem G. Inhibition of endothelial cell proliferation by heparin and steroids. Cell Biol Int Rep 1988; 12: 1037–47.

Rosenbaum J. Tobelem G. Molko P. Barzu T. Caen J. P. Modulation of endothelial cell growth induced by heparin. Cell Biol Int Rep 1986; 10: 437–46.

Tobelem G. Endothelial cell interactiions with heparin. Semin Thromb Haemost 1989; 15: 197–99.

Glimelius B. Busch C. Höök M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978; 12: 773–82.

Terranova V P Diflorio R. Lyall R M Hic S. Friesel R. Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330–34.

Ulrich S. Lagente O. Lenfant M. Courtois Y. Effect of heparin on the stimulation of non-vascular cells by human acidic and basic FGF. Biochem Biophys Res Commun 1986; 137: 1205–13.

Gospodarowicz D. Cheng J. Heparin protects basic and acidic FUF from inactivation. J Cell Physiol 1986; 128: 475–84.

Blajchman M A Young E. Ofusu F. A. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 1989; 556: 245.

Hubbard A R Jennings C. A. Inhibition of tissue thromboplastin-mediated blood coagulation. Thromb Res 1986; 42: 489–98.

Broze G J Jr Miletich J. P. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150–55.

Lindahl A K Sandset P M Abildgaard U. The present status of the tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439–49.

Bajaj M S Rana S V Wysolmerski R B Bajaj S. P. Inhibitor of the factor VIIa–tissue factor complex is reduced in patients with desseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874–78.

Colburn P. Bounassisi V. Identification of an endothelial cell product as an inhibitor of tissue factor activity. In Vitro: Cell Dev Biol 1988; 24: 1133–36.

Warn-Cramer B J Almus F E Rapaport S. I. Studies of the Factor Xa-dependent inhibitor of Factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernatates of cultured human umbilical vein endothelial cells. Thromb Haemost 1989; 61: 101–105.

Bajaj M S Kuppuswamy M N Saito H. Spitzer S G Bajaj S. P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Nat Acad Sci USA 1990; 87: 8869–73.

Sandset P M Abildgaard U. Larsen M. L. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803–13.

Lindahl A K Abildgaard U. Stokke G. Release of extrinsic pathway inhibitor after heparin injection: Increased response in cancer patients. Thromb Res 1990; 59: 651–56.

Lindahl A K Abildgaard U. Larsen M L Aamodt L-M Nordfang O. Beek T. C. Extrinsic pathway inhibitor (EPI), and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res 1991; suppl XIV: 39–48.

Lindahl A K Abildgaard U. Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155–68.

Holst J. Lindblad B. Bergqvist D. . Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor (rTFPI1–161) in an experimental venous thrombosis model. Haemostasis 1993; 23 (suppl 1): 112–17.

Wun T-C. Lipoprotein-associated coagulation inhibitor (LAC I) is a cofactor for heparin: Synergistic anticoagulant action between LAC I and sulfated polysaccharides. Blood 1992; 79: 430–38.

Vairel E G Bouty-Boye H. Toulemonde F. Doutremepuich C. Marsh N A Gaffney P. J. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219–24.

Agnelli G. Borm J. Cosmi B. Levi M. ten Cate Wouter J. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1988; 60: 311–13.

Fears R. Kinetic studies on the effect of heparin and fibrin on plasminogen activators. Biochem J 1988; 249: 77–81.

Andrade-Gordon P. Strickland S. Anticoagulant low molecular weight heparin does not enhance the activation of plasminogen by tissue plasminogen activator. Biochem J 1989; 264: 15177–81.

Neerstrand H. Østergaard P. Bergqvist B. Mätzsch T. Hedner U. tPA inhibitor, tPA:Ag, plasminogen, and α2-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987; I: 39–43.

Eriksson E. Wolter I M Christenson B. Stigendal L. Risberg B. Heparin and fibrinolysis — comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Haemost 1988; 59: 284–88.

Aranda A. Páramo J A Alfaro M J Rocha E. The influence of standard and low molecular weight heparin on fibrinolysis in patients undergoing major abdominal surgery. Biol Clin Hematol 1987; 9: 169–74.

Ljungberg B. Johnsson H. In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent haemostasis in dogs. Thromb Haemost 1988; 60: 232–35.

Grimande V. Omri A. Kruithof E K O Hauert J. Bachmann F. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparindihydroergotamine combination. Thromb Haemost 1988; 59: 388–91.

Arnesen H. Engebretsen L F Ugland O M Seljeflot J. Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1989; 56: 649–53.

Klein P. Plasma levels of t-PA:Ag under standard heparin therapy. Thromb Res 1989; 56: 649–53.

Melissari E. Scully M F Paes T. Kakkar V. V. The influence of LMW heparin on the coagulation and fibrinolytic response to surgery. Thromb Res 1985; 37: 115–26.

Brunkwall J. On prostanoid release from animal and human vessels in an ex vivo perfusion model. Thesis, Malmö, 1990.

Brunkwall J. Mätzsch T. Bergqvist D. The effect of unfractionated and low-molecular-weight heparin on the release of prostacyclin from the arterial wall. Blood Coagul Fibrinolysis 1990; 1: 641–45.

Kresowik T F Vincent C K Brunkwall J S Stanley J. C. Effect of preexcisional heparin anticoagulation on excised canine vein and artery prostanoid production. J Surg Res 1989; 46: 605–10.

Ljungberg B. Beving H. Egberg N. Johnson H. Vesterqvist O. Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors. Thromb Res 1988; 51: 209–17.

Kaji T. Yamamoto C. Sakamoto M. Low molecular weight heparin enhances prostacyclin production by cultured human endothelial cells. Chem Pharm Bull 1991; 39: 3368–69.

Doni M G Piva E. Warfarin and heparin interaction with prostacyclin-like activity generated by arterial wall in the rat. Thromb Haemost 1983; 49: 228–29.

Kaji T. Sakuragawa N. Heparin stimulates the release of glycosaminoglycans from cultured human endothelial cells. Thromb Res 1990; 57: 163–68.

Chervu A. Moore W. S. An overview of intimal hyperplasia. Surg Gynecol Obstet 1990; 171: 433–47.

Clowes A W Karnovsky M. J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625–26.

Hoover R L Rosenberg R. Haering W. Karnovsky M. J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980; 47: 578–83.

Majack R A Clowes A. W. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118: 253–56.

Clowes A W Clowes M. M. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985; 52: 611–16.

Clowes A W Clowes M. M. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 1986; 58: 839–45.

Majesky M. Reidy M. Benditt E P Schwartz S. Expression of platelet-derived growth factor (PDGF) A- and B-chain gene in smooth muscle during repair of arterial injury. J Mol Cell Cardiol 1987; 19 (suppl IV): S3.

Paul R. Herbert J M Maffrand J P . Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds. Thromb Res 1987; 46: 793–801.

Castellot J J Choay J. Lormean J-C Petitou M. Sache E. Karnovsky M. J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence containing a 3-O-sulfate group. J Cell Biol 1986; 102: 1979–84.

Snow A D Bolender R P Wight T N Clowes A. W. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313–30.

Mason R. Williams S. Heparin induces synthesis of highly charged heparin sulphate by vascular smooth muscle cells. Biochem Soc Trans 1990; 18: 965.

Guyton J R Rosenberg R D Clowes A W Karnovsky M. J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980; 46: 625–34.

Dryjski M. Mikat E. Bjornsson T. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid. J Vasc Surg 1988; 8: 623–33.

Castellot J J Wong K. Herman B. . Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985; 124: 13–20.

Kenagy R D Clowes A. W. Inhibition of mitogenesis by heparin is related to the degree but not type of mitogenic stimulation. J Cell Biol 1986; 103: 34a.

Seldon S. C. Heparin inhibition of cell cycle travers in human vascular smooth muscle cells in vitro. J Cell Biol 1986; 103: 349.

Reilly T C Fritze L M S Rosenberg R. Heparin inhibition of smooth muscle cell proliferation: A cellular site of action. J Cell Physiol 1986; 129: 11–19.

Wright T C Karnovsky M. J. Metabolic effects of heparin on rat cervical epithelial cells. J Cell Physiol 1987; 132: 255.

Castellot J J Addonizio M L Rosenberg R D Karnovsky M. J. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981; 90: 372–79.

Castellot J J Cochran D L Karnovsky M. J. Effects of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 1985; 124: 21–28.

Majack R A Bornstein P. Heparin regulates the collagen phenotype of vascular smooth muscle cells: Induced synthesis of an M2 60 000 collagen. J Cell Biol 1985; 100: 613–19.

Cochran D L Castellot J J Karnovsky M. J. Effect of heparin on vascular smooth muscle cells. II. Specific protein synthesis. J Cell Physiol 1985; 124: 29–36.

Tiozzo R. Reggiani D. Cingi M R Bianchini P. Osima B. Calandra S. Effect of heparin derived fractions on the proliferation and protein synthesis of cells in culture. Thromb Res 1991; 62: 177–88.

Majack R A Bornstein P. Heparin and related glycosaminoglycans modulates the secretory phenotype of vascular smooth muscle cells. J Cell Biol 1984; 99: 1688–95.

Majck R A Cook S C Bornstein P. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol 1985; 101: 1059–70.

Castellot J J Beeler D L Rosenberg R D Karnovsky M. J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984; 120: 315–20.

Choay J. Petitou M. Lormean J-C Sinay P. Casu B. Gatti G. Structure–function relationships in heparin: A synthetic with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492–99.

Currier J W Pow T K Haudenschild C C Minihan A C Faxon D. P. Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 118B–25B.

Edelman E R Adams D H Karnovsky M. J. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA 1990; 87: 3773–77.

Okada T. Bark D. Mayberg M. Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 1989; 25: 892–98.

Hanke H. Oberhoff M. Hanke S. . Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation 1992; 85: 1548–56.

Kohler T R Kirkman T. Clowes A. W. Effect of heparin on adaptation of vein grafts to arterial circulation. Arteriosclerosis 1989; 9: 523–28.

Wilson N V Salisbury J R Kakkar V. V. Effect of low molecular weight heparin on intimal hyperplasia. Br J Surg 1991; 78: 1381–83.

Rodgers G P Minor S T Robinson K. . Adjuvant therapy for intracoronary stents: Investigations in atherosclerotic swine. Circulation 1990; 82: 560–69.

Schatz R A Palmaz J C Tio F O Garcia O. Reuter S. R. Balloon-expandable intracoronary stents in the adult dog. Circulation 1987; 76: 450–57.

Buchwald A. Unterberg C. Nebendahl K. Gröne H. Wiegand V. Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation 1992; 86: 531–37.

Ellis S. Roubin G. Wilentz J. Douglas J. King S. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777–82.

Weiss S. J. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365–76.

Roos D. Neutrophils. In: Roitt I M Delves P J eds. Encyclopedia of immunology. London: Academic Press, 1992: 1092–93.

Van Furth R. Monocytes. In: Roitt I M Delves P J eds. Encyclopedia of immunology. London: Academic Press, 1992: 1163–66.

Leculier C. Benzerara O. Couprie N. . Specific binding between human neutrophils and heparin. Br J Haematol 1992; 81: 81–85.

Leung L. Harpel P C Nachman R L Rabellino E. M. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016.

Matzner Y. Marx G. Drexler R. Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52(2): 134–37.

Zigmond S H Hirsch J G , Leukocyte locomotion and chemotaxis: New methods for evaluation and demonstration of cell-derived chemotactic factor. J Exp Med 1973; 137: 387–410.

Chenoweth D. Hugli T. E. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943–47.

Strunk R. Colten H. R. Inhibition of the enzymatic activity of the first component of complement (C1) by heparin. Clin Immunol Immunopathol 1976; 6: 248–55.

Loos M. Volanakis J E Stroud R. M. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement – III: Inhibition of C4 and C2 binding sites on C1s by polyanions. Immunochemistry 1976; 13: 789–91.

Caughman G B Boackle R J Vesely J. A postulated mechanism for heparin's potentiation of C1 inhibitor function. Mol Immunol 1982; 19: 287–95.

Hennink W E Klerx J P A M Van Dijk H. Feijen J. Complement inhibitory and anticoagulant activities of fractionated heparins. Thromb Res 1984; 36: 281–92.

Freischlag J A Colburn M D Quinones-Baldrich W J Moore W. S. Heparin, urokinase, and ancrod alter neutrophil function. J Vasc Surg 1992; 16: 565–74.

Pasini Laghi F. Pasqui A L Ceccatelli I. Di Perri T. Heparin inhibits FMLP and Con A dependent activation of human polymorphonuclear leukocytes in vitro. Int J Tissue React 1983; 5: 145–51.

Laghi-Pasini F. Pasqui A L Ceccatelli L. Capecchi P L Orrico A. Di Perri T. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to ganulocyte-mediated vascular damage. Thromb Res 1984; 35: 527–37.

Victor M. Weiss J. Elsbach P. Heparin inhibits phagocytosis by polymorphonuclear leukocytes. Infect Immun 1981; 32: 295.

Cairo M S Allen J. Higgins C. Baehner R L Boxer L. A. Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation. Am J Pathol 1983; 113: 67–74.

Håkansson L. Hällgren R. Venge P. Regulation of granulocyte function by hyaluronic acid. In vitro and in vivo effects on phagocytosis, locomotion and metabolism. J Clin Invest 1980; 66: 298.

Furie B. Furie B. C. Molecular and cellular biology of blood coagulation. New Engl J Med 1992; 329: 800–806.

Doutremepuich C. Toulemonde F. De Seze O. Pereira F. Anne M C Doutremepuich F. Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model. J Leukocyte Biol 1987; 42: 628–31.

Doutremepuich C. Anne C. Pereira F. . Role of heparin and heparin fraction in leukocyte count. An experimental study. Ann N Y Acad Sci 1989; 556: 432–34.

Van Damme J. Interleukin-8 and related molecules. In: Thompsen A. ed. The cytokine handbook. London: Academic Press, 1991: 201–14.

Henson P M Henson J E Fittschen C. Kimani G. Bratton D L Riches D. W. H. Phagocytic cells: Degranulation and secretion. In: Gallin J. Gottstein J M Snyderman R. eds. Inflammation. New York: Raven Press, 1988: 363–90.

Selak M A Chignard M. Smith J. B. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988; 251: 293–99.

Ferrer-Lopez P. Renesto P. Prevost M C Gounon P. Chignard M. Heparin inhibits neutrophil-induced platelet activation via cathepsin G. J Lab Clin Med 1992; 119: 231–39.

Selak M A Smith J. B. Cathepsin G binding to human platelets. Evidence for a specific receptor. Biochem J 1990; 266: 55–62.

Marossy K. Interaction of the chymotrypsin- and elastase-like enzymes of the human granulocyte with glycosaminoglycans. Biochim Biophys Acta 1981; 659: 351–61.

Redini F. Tixier J M Petitou M. Choay J. Robert L. Hornebeck W. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 1988; 252: 515–19.

Jacques L. B. Heparins. Anionic polyelectrolyte drugs. Pharmacol Rev 1979; 31: 99–166.

Schmidt W. Egbring R. Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human elastases. Eur J Biochem 1975; 42: 519–27.

Hastka J. The importance of granulocyte elastase in haematoogical diagnosis. Blut 1988; 57: 69–75.

Jochum M. Lander S. Heimburger N. Fritz H. Effect of human granulocytic elastase on isolated human antithrombin III. Hoppe-Seyler's Z Physiol Chem 1981; 362: 103–12.

Jordan R E Nelson R M Kilpatrick J. Newgren J O Esmon P C Fournel M. A. Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. J Biol Chem 1989; 264: 10493–500.

Jordan R E Kilpatrick J. Nelson R. M. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987; 237: 777–79.

Yoffe J R Taylor D J Woolley D. E. Mast-cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte/macrophages. Biochem J 1985; 230: 83–88.

Leung L. Saigo K. Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood 1989; 73: 177–84.

Kjellen L. Oldberg A. Rubin K. Höök M. Binding of heparin and heparin sulfate to rat liver cells. Biochem Biophys Res Commun 1977; 74: 126.

Bleiberg I. MacGregor I. Aronson M. Heparin receptors on mouse macrophages. Thromb Res 1983; 29: 53.

Chong A S F Parish C. R. Cell surface receptors for sulfated polysaccharides: A potential marker for macrophages subsets. Immunlogy 1986; 58: 277–84.

Lijnen H R Hoylaerts M. Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803.

Copley A L Robb T. B. Studies on platelets. III. The effect of heparin in vivo on the platelet count in mice and dogs. Am J Clin Pathol 1942; 12: 563.

Fidlar E. Jaques L. B. The effect of commercial heparin on the platelet count. J Lab Clin Med 1948; 33: 1410.

Bell W R Royall R. M. Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 1980; 3093: 902–907.

Schwartz K A Royer G. Kaufman D B Penner J. A. Complications of heparin administration in normal individuals. Am J Hematol 1985; 19: 355–63.

Kelton J G , Heparin-induced thrombocytopenia. Haemostasis 1986; 16: 173.

Heiden D. Mielke C H Rodvien R. Impairment by heparin of primary haemostasis and platelet (14C)5-hydroxytryptamine release. Br J Haematol 1977; 36: 427.

Salzman E W Rosenberg R D Smith M H Lindon J N Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64–73.

Saba H I Saba S R Morelli G. A. Effect of heparin on platelet aggregation. Am J Hematol 1984; 17: 295–306.

Sobel M. Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988; 50: 815–26.

Horne M. K. Heparin binding to normal and abnormal platelets. Thromb Res 1988; 51: 135–44.

Horne M K Chao E. S. Heparin binding to resting and activated platelets. Blood 1989; 74: 238–43.

Gogstad G O Solum N O Krutnes M. B. Heparin-binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis. Br J Haematol 1983; 53: 563–73.

Wolf H. Glassl H. Nowack H. Wick G. Identification of binding site for heparin and other polysulfated glycosaminoglycans on human thrombocytes. Int Arch Allergy Appl Immunol 1986; 80: 231–38.

Horne M K Chao E. S. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74: 306–12.

Brace L D Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 1985; 11: 190.

Brace L D Fareed J. Heparin-induced platelet aggregation: Dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions. Thromb Res 1986; 42: 769–82.

Mastacchi R. Stanzani L. Barbanti M. Montecchi L. Bianchini P. Interaction of heparin and heparin fractions with human platelets. Thromb Res 1982; 28: 275–80.

Westwick J. Scully M F Poll C. Kakkar V. V. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986; 42: 435–47.

Barradas M A Mikhailidis D P Epemolu O. Jeremy J Y Fonseca V. Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987; 67: 451–57.

Dunn F. Soria J. Soria C. Thomaides A. Tobelem G. Caen J. P. Fibrinogen binding on human platelets. Influence of different heparins and of pentosane polysulfate. Thromb Res 1983; 29: 141–48.

Heinrich D. Görg T. Schulz M. Effects of unfractionated and fractionated heparin on platelet function. Haemostasis 1988; 18 (suppl 3): 48–54.

Chen J. Karlberg K-E Sylvén C. Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers. Thromb Res 1991; 63: 319–29.